Internal Medicine, Hematology & Oncology · Brooklyn, NY
NPI
1215991070
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
5
Medicare group memberships
Hospitals
1
Hospital affiliations
566 Schenectady Ave
Brooklyn, NY, 11203
Phone (718) 483-8360
Groups this clinician bills Medicare through
Medicare paid, 2024
$82K
1,406 services
Medicare patients, 2024
304
Average age 70
Drug cost, 2024
$2.0M
1,131 prescriptions
Company payments, 2025
$1,070
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Madhumati R Kalavar was code 99232 (hospital e&m - subsequent), 383 times for 145 patients. In total Madhumati R Kalavar billed 1,406 services in 24 codes, and Medicare paid $82K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-06-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 383 | 145 | $70.40 | $27K |
| 99214 Office E&M - Established | Facility | 161 | 73 | $80.80 | $13K |
| 99222 Hospital E&M - Initial | Facility | 139 | 122 | $114.44 | $16K |
| 99213 Office E&M - Established | Office | 84 | 26 | $75.13 | $6,311 |
| 99214 Office E&M - Established | Office | 50 | 25 | $106.62 | $5,331 |
| 36415 Venipuncture Blood Collection | Office | 37 | 18 | $8.65 | $320 |
| 99213 Office E&M - Established | Facility | 36 | 28 | $54.79 | $1,972 |
| 99204 Office E&M - New | Facility | 22 | 22 | $109.21 | $2,403 |
By year: 2022 $83K for 1,421 services; 2023 $67K for 1,161 services; 2024 $82K for 1,406 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 37 | 18 | $8.65 | $320 |
Medicare prescription drug claims, 2024
In 2024, the drug Madhumati R Kalavar prescribed most often to Medicare patients was Anastrozole, with 73 prescriptions and refills. In total Madhumati R Kalavar wrote 1,131 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 73 | 149 | 19 | $733 |
| Sodium Chloride 0.9 % Sodium Chloride | 71 | 71 | 14 | $308 |
| Bortezomib Generic | 60 | 60 | Under 11 | $164K |
| Dexamethasone Sodium Phosphate Generic | 57 | 57 | Under 11 | $81.08 |
| Granisetron Hcl Generic | 52 | 54 | Under 11 | $463 |
| Diphenhydramine Hcl Generic | 46 | 46 | Under 11 | $58.97 |
| Hydroxyurea Generic | 45 | 57 | Under 11 | $707 |
| Eliquis Apixaban | 43 | 46 | 13 | $26K |
| Abiraterone Acetate Generic | 38 | 40 | Under 11 | $181K |
| Dexamethasone Generic | 36 | 36 | Under 11 | $361 |
| Granisetron Hcl Granisetron Hcl/Pf | 35 | 35 | Under 11 | $353 |
| Famotidine Famotidine/Pf | 30 | 30 | Under 11 | $33.63 |
| Lenalidomide Generic | 30 | 30 | Under 11 | $327K |
| Xgeva Denosumab | 28 | 30 | Under 11 | $86K |
| Prednisone Generic | 27 | 33 | 11 | $96.35 |
Brand drugs: 280 claims; generic drugs: 851 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Madhumati R Kalavar $1,070 ($1,070 in general payments such as food, travel and fees) from 18 companies. The largest payer was Janssen Biotech, Inc. with $254.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 14 | $254 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $183 |
| Pfizer Inc. PFE | 3 | $72.64 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $68.98 |
| Incyte Corporation INCY | 3 | $56.73 |
| Puma Biotechnology, Inc. PBYI | 3 | $54.15 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $44.07 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $44.01 |
| Exelixis Inc. EXEL | 2 | $40.24 |
| Celgene Corporation BMY | 2 | $38.3 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.